Developer docs
API playgroundTry for free, no card

Search company profiles

Arrowhead Pharmaceuticals

Full company profile

uuid0000f9j

Namestring
Arrowhead Pharmaceuticals
Legal namestring
Arrowhead Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Arrowhead Pharmaceuticals is a clinical-stage-to-commercial biotechnology company that develops RNA interference (RNAi) therapeutics using its proprietary Targeted RNAi Molecule (TRiM™) platform. The platform leverages the natural RNAi gene-silencing pathway to silence disease-causing genes and is engineered to deliver RNAi payloads subcutaneously across multiple tissue types including liver, lung, muscle, and — uniquely — the central nervous system via a proprietary blood-brain barrier crossing delivery system. The company is headquartered in Pasadena, California, employs 501-1,000 people, and trades on NASDAQ under ticker ARWR. It operates research facilities in Madison and San Diego, a manufacturing site in Verona, Wisconsin, and a European regional office in Dublin, Ireland.

The company transitioned to commercial-stage status in November 2025 when the FDA approved REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS), a rare genetic disease affecting approximately 6,500 patients in the United States. REDEMPLO is priced at $60,000 per year, distributed exclusively through Vanscoy Rare Pharmacy, and has generated 100 prescriptions in its first 10 weeks. The company subsequently secured approvals in Canada, China, Australia, and the EU. The clinical pipeline spans 14+ programs across cardiometabolic disease (plozasiran for severe hypertriglyceridemia, zodasiran for homozygous familial hypercholesterolemia), obesity (ARO-INHBE and ARO-ALK7 with differentiated efficacy versus GLP-1 monotherapy), pulmonary conditions (ARO-RAGE), and CNS (ARO-MAPT for Alzheimer's tauopathies). ARO-DIMER-PA represents a first-in-class dual-gene RNAi therapeutic for mixed hyperlipidemia.

Arrowhead's business model combines direct product sales of REDEMPLO with substantial licensing and milestone revenue from major pharmaceutical partners. Major deals include Sarepta Therapeutics ($825 million upfront, up to $10 billion in potential milestones), Novartis ($200 million upfront, up to $2.2 billion in potential milestones), Takeda (co-development of ARO-AAT), and Madrigal Pharmaceuticals (ARO-PNPLA3 for MASH). The company has raised approximately $930 million through public equity and convertible notes offerings in 2024-2026 and secured a $500 million non-dilutive credit facility from Sixth Street. FY2025 revenue reached approximately $829 million driven by partner milestone payments, and the company achieved profitability in FY2026 Q1 with $30.8 million in net income.

Short descriptiontext

Arrowhead Pharmaceuticals is a commercial-stage biotechnology company developing RNA interference (RNAi) therapeutics via its proprietary TRiM™ platform to silence disease-causing genes across liver, lung, muscle, and CNS tissues. It markets REDEMPLO for familial chylomicronemia syndrome and licenses pipeline assets to partners including Sarepta and Novartis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersPasadena, United States
HQ citystring
Pasadena
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA interference therapeutics, siRNA drug development, cardiometabolic biopharmaceuticals, rare disease medicines, targeted gene silencing
Industry8 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
RNAi Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales
TypeOne Time License
Description

Commercial revenue from approved drug REDEMPLO (plozasiran) for familial chylomicronemia syndrome, priced at $60,000 annually. The company achieved 100 prescriptions in the first 10 weeks post-launch.

businesswire.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Major licensing agreements including Sarepta ($825M upfront, up to $10B total potential), Novartis ($200M upfront, up to $2.2B total potential), and Madrigal ($25M upfront, up to $1B total potential). Revenue recognized upon milestone achievements and upfront payments.

ir.arrowheadpharma.com
3Milestone Payments
TypeLicensing Royalties
Description

Development and regulatory milestone payments from partners including $200M from Sarepta for DM1 program progress, $200M from Novartis for Parkinson's partnership close, and $10M from Sanofi for China approval of REDEMPLO.

tradingview.com
4Strategic Financing
TypeHardware Sales
Description

Non-dilutive $500M credit facility with Sixth Street ($400M funded at close, $100M additional available) with maturity August 7, 2031. Used to fund pipeline development and commercial readiness.

ir.arrowheadpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1REDEMPLO annual treatment at $60,000/year
ModelUnit PricingBilling cadenceAnnual
Notes

$60,000 annual price for REDEMPLO (plozasiran) for FCS patients. Self-administered via subcutaneous injection every three months. Commercial launch exceeded early expectations with 100 prescriptions in first 10 weeks.

investing.com
2REDEMPLO approved in US, Canada, China, Australia, and EU
ModelUnit PricingBilling cadenceAnnual
Notes

Pricing consistent across major markets. European approval granted June 2026, following approvals in US (November 2025), Canada (January 2026), China (January 2026), and Australia (May 2026).

financialcontent.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1REDEMPLO
Description

Brand name for plozasiran, the company's first FDA-approved siRNA medicine for familial chylomicronemia syndrome (FCS).

biospace.com
+1 more record
Core offering1 text field

Arrowhead Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics using its proprietary Targeted RNAi Molecule (TRiM) platform, which silences disease-causing genes across multiple tissue types including liver, lung, muscle, and CNS. The company currently markets REDEMPLO (plozasiran), an FDA-approved siRNA medicine for familial chylomicronemia syndrome, and is advancing a pipeline of over 14 clinical-stage RNAi candidates addressing cardiometabolic, pulmonary, CNS, and rare genetic diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • REDEMPLO achieved 80% median triglyceride reduction from baseline in FCS patients (Phase 3 PALISADE trial)
+5 more records
Product overview1 text field

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company that develops RNAi (RNA interference) therapeutics using its proprietary TRiM (Targeted RNAi Molecule) platform. The company has transitioned from a development-stage to a commercial-stage company following FDA approval of its first drug, REDEMPLO (plozasiran), in November 2025. The portfolio includes approved and pipeline products: REDEMPLO (plozasiran) for familial chylomicronemia syndrome is the company's first approved commercial product; Plozasiran (ARO-APOC3) is in Phase 3 for severe hypertriglyceridemia; Zodasiran (ARO-ANG3) is in Phase 3 for homozygous familial hypercholesterolemia; ARO-RAGE is in Phase 2 for inflammatory pulmonary diseases; obesity candidates ARO-INHBE and ARO-ALK7 are in Phase 1/2a; ARO-MAPT for Alzheimer's disease is in Phase 1/2a; and ARO-DIMER-PA for mixed hyperlipidemia is in Phase 1/2a. The TRiM platform enables targeted gene silencing across multiple tissue types.

Product and service8 records
1REDEMPLO (plozasiran)
CategoryCommercial RNAi Therapeutic
Description

FDA-approved siRNA medicine that reduces Apolipoprotein-CIII (ApoC3) production through RNA interference to lower triglycerides in adults with familial chylomicronemia syndrome (FCS). Approved in the US, Canada, China, Australia, and the EU.

2Plozasiran (ARO-APOC3)
CategoryPipeline RNAi Therapeutic
Description

RNAi therapeutic in Phase 3 development for severe hypertriglyceridemia (SHTG), targeting ApoC3 to reduce triglyceride production. Pipeline expansion of the plozasiran program beyond the FCS indication.

3Zodasiran (ARO-ANG3)
CategoryPipeline RNAi Therapeutic
Description

RNAi therapeutic in Phase 3 development (YOSEMITE study) that reduces production of angiopoietin-like protein 3 (ANGPTL3), a liver-synthesized inhibitor of lipoprotein lipase, targeting cardiovascular disease and homozygous familial hypercholesterolemia.

4ARO-RAGE
CategoryPipeline RNAi Therapeutic
Description

RNAi therapeutic in Phase 2 development targeting the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.

5ARO-INHBE
CategoryPipeline RNAi Therapeutic
Description

RNAi therapeutic in Phase 1/2a development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), targeting the INHBE gene for differentiated weight loss and liver fat reduction.

6ARO-ALK7
CategoryPipeline RNAi Therapeutic
Description

RNAi therapeutic in Phase 1/2a development for obesity, the first RNAi therapeutic to show knockdown of an adipocyte-expressed gene in humans. Targets the ALK7 gene for visceral fat reduction.

7ARO-MAPT
CategoryPipeline RNAi Therapeutic
Description

Investigational RNAi therapeutic in Phase 1/2a development designed to treat tauopathies including Alzheimer's disease. Uses the proprietary TRiM platform with subcutaneous delivery that crosses the blood-brain barrier to target tau protein (MAPT).

8ARO-DIMER-PA
CategoryPipeline RNAi Therapeutic
Description

First dual functional RNAi therapeutic in Phase 1/2a development for mixed hyperlipidemia, targeting both ANGPTL3 and ApoC3 simultaneously.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Licensed ARO-PNPLA3, an RNAi candidate targeting PNPLA3 I148M genetic mutation for MASH, to Madrigal Pharmaceuticals. Arrowhead received $25 million upfront with potential milestone payments totaling up to $975 million. The asset had been returned to Arrowhead after J&J rejected it. Madrigal intends to add ARO-PNPLA3 to its growing pipeline alongside FDA-approved Rezdiffra.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-10
Description

Co-development and co-commercialization agreement for ARO-AAT (fazirsiran) for Alpha-1 Antitrypsin Deficiency-associated liver disease. Arrowhead earned $40 million milestone when first patient was treated in Phase 3 SEQUOIA study. Takeda acquired additional programs from Arrowhead.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-02
Description

Global license and collaboration agreement for ARO-SNCA targeting alpha-synuclein for Parkinson's disease and other synucleinopathies. Arrowhead received $200 million upfront payment with potential milestone payments up to $2 billion plus royalties. Arrowhead conducted preclinical research through CTA filing, after which Novartis assumes sole control over development, manufacturing, medical affairs, and commercialization. Deal closed in October 2025.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-01
Description

Arrowhead subsidiary Visirna sold rights to plozasiran (hypertriglyceridemia candidate) in Greater China to Sanofi. Sanofi also received $10 million milestone payment from Arrowhead following China's approval of REDEMPLO for FCS in January 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-26
Description

Global licensing and collaboration agreement for multiple clinical and preclinical RNAi programs targeting rare genetic diseases. Arrowhead received $825 million upfront payment with potential future payments up to $10 billion including milestones and royalties. Programs include SRP-1001 (FSHD), SRP-1003 (DM1), SRP-1005 (Huntington's), and additional candidates. Sarepta paid $500 million for rights to seven programs. Arrowhead earned $200 million milestone for DM1 program progress and $100 million milestone in July 2025.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2024-10-31
Description

Janssen partnership ended in 2023 after Janssen cut its infectious disease and vaccine units. Johnson & Johnson liquidated its Arrowhead stake in 2026, exiting the relationship. Roche collaboration on hepatitis B programs continued through various arrangements.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The leading siRNA therapeutics company and the closest direct peer. Alnylam has multiple approved siRNA drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio) and a similar platform-based approach to gene silencing. Both companies compete for the same large-pharma partnership economics and target overlapping indications.

TypeDirect peer
Description

Direct competitor in antisense oligonucleotide therapeutics with an approved FCS drug (Tryngolza/olezarsen) that competes head-to-head with Arrowhead's REDEMPLO. Ionis and Arrowhead target the same cardiometabolic and rare disease indications through RNA-based approaches, making them direct strategic peers.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company developing stereopure oligonucleotide therapeutics. Comparable to Arrowhead in being an RNA-focused biotech with similar pipeline-stage assets and partnership-driven business model, though smaller and earlier-stage.

TypeEmerging player
Description

Clinical-stage siRNA therapeutics company developing mRNAi GOLD platform. Comparable to Arrowhead as an siRNA-focused player with cardiovascular pipeline assets (e.g., SLN360 for Lp(a)). Smaller and earlier-stage but pursues similar siRNA therapeutic strategy.

TypeEmerging player
Description

MASH-focused biopharma with FDA-approved Rezdiffra, and a current Arrowhead partner (licensed ARO-PNPLA3 in May 2026). Comparable commercial-stage liver/metabolic biotech that validates Arrowhead's MASH pipeline asset and illustrates the typical scale and profile of Arrowhead's partner counterparties.

TypeBroad incumbent
Description

Arrowhead's largest strategic partner ($10B potential deal), and a leading rare-disease genetic medicine company. While not a direct therapeutic competitor (Sarepta focuses on gene therapy/DMD), it is a benchmark partner of comparable scale and validates the platform's commercial appeal.

TypeBroad incumbent
Description

Broader RNA therapeutics incumbent (mRNA-based) with established platform, commercial product, and large-scale manufacturing. Comparable as a public RNA-therapeutics leader but operates with different technology (mRNA vs siRNA) and at greater scale across infectious disease and oncology.

TypeBroad incumbent
Description

mRNA therapeutics leader with diversified pipeline in oncology and infectious disease. Comparable as a public, platform-based RNA therapeutics company with similar scientific ambitions and capital markets profile, though at much larger scale.

TypeEmerging player
Description

Clinical-stage rare disease biopharma focused on FcRn inhibitors (autoimmune) and anti-IGF-1R antibodies (thyroid eye disease). Comparable commercial-stage rare-disease biotech at similar development phase and market cap tier to Arrowhead's pre-launch REDEMPLO era.

TypeOthers
Description

Financial partner that purchased Arrowhead's olpasiran royalty interest for $250M in 2024. Listed as an ecosystem/adjacent participant that funds biopharma innovation through royalty transactions, illustrating the broader capital-market infrastructure that supports RNAi asset development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arrowhead Pharmaceuticals

RNAi Biopharmaceuticalsarrowheadpharma.com

Arrowhead Pharmaceuticals is a commercial-stage biotechnology company developing RNA interference (RNAi) therapeutics via its proprietary TRiM™ platform to silence disease-causing genes across liver, lung, muscle, and CNS tissues. It markets REDEMPLO for familial chylomicronemia syndrome and licenses pipeline assets to partners including Sarepta and Novartis.

What Arrowhead Pharmaceuticals does

Arrowhead Pharmaceuticals is a clinical-stage-to-commercial biotechnology company that develops RNA interference (RNAi) therapeutics using its proprietary Targeted RNAi Molecule (TRiM™) platform. The platform leverages the natural RNAi gene-silencing pathway to silence disease-causing genes and is engineered to deliver RNAi payloads subcutaneously across multiple tissue types including liver, lung, muscle, and — uniquely — the central nervous system via a proprietary blood-brain barrier crossing delivery system. The company is headquartered in Pasadena, California, employs 501-1,000 people, and trades on NASDAQ under ticker ARWR. It operates research facilities in Madison and San Diego, a manufacturing site in Verona, Wisconsin, and a European regional office in Dublin, Ireland.

The company transitioned to commercial-stage status in November 2025 when the FDA approved REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS), a rare genetic disease affecting approximately 6,500 patients in the United States. REDEMPLO is priced at $60,000 per year, distributed exclusively through Vanscoy Rare Pharmacy, and has generated 100 prescriptions in its first 10 weeks. The company subsequently secured approvals in Canada, China, Australia, and the EU. The clinical pipeline spans 14+ programs across cardiometabolic disease (plozasiran for severe hypertriglyceridemia, zodasiran for homozygous familial hypercholesterolemia), obesity (ARO-INHBE and ARO-ALK7 with differentiated efficacy versus GLP-1 monotherapy), pulmonary conditions (ARO-RAGE), and CNS (ARO-MAPT for Alzheimer's tauopathies). ARO-DIMER-PA represents a first-in-class dual-gene RNAi therapeutic for mixed hyperlipidemia.

Arrowhead's business model combines direct product sales of REDEMPLO with substantial licensing and milestone revenue from major pharmaceutical partners. Major deals include Sarepta Therapeutics ($825 million upfront, up to $10 billion in potential milestones), Novartis ($200 million upfront, up to $2.2 billion in potential milestones), Takeda (co-development of ARO-AAT), and Madrigal Pharmaceuticals (ARO-PNPLA3 for MASH). The company has raised approximately $930 million through public equity and convertible notes offerings in 2024-2026 and secured a $500 million non-dilutive credit facility from Sixth Street. FY2025 revenue reached approximately $829 million driven by partner milestone payments, and the company achieved profitability in FY2026 Q1 with $30.8 million in net income.

Arrowhead Pharmaceuticals firmographics

Firmographics
Name
Arrowhead Pharmaceuticals
Legal name
Arrowhead Pharmaceuticals, Inc.
Website
https://arrowheadpharma.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Arrowhead Pharmaceuticals is a commercial-stage biotechnology company developing RNA interference (RNAi) therapeutics via its proprietary TRiM™ platform to silence disease-causing genes across liver, lung, muscle, and CNS tissues. It markets REDEMPLO for familial chylomicronemia syndrome and licenses pipeline assets to partners including Sarepta and Novartis.
Ownership category
akta.pro rank

Arrowhead Pharmaceuticals industry classification

Industry
Product category
RNAi Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAJ
RNA Therapeutics Regulatory, Quality & Pharmacovigilance (GxP, comparability, post-market)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAI
RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA interference therapeutics
  • SiRNA drug development
  • Cardiometabolic biopharmaceuticals
  • Rare disease medicines
  • Targeted gene silencing

Where Arrowhead Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Pasadena
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Arrowhead Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Product Sales: Commercial revenue from approved drug REDEMPLO (plozasiran) for familial chylomicronemia syndrome, priced at $60,000 annually. The company achieved 100 prescriptions in the first 10 weeks post-launch.
  2. Licensing and Milestone Payments: Major licensing agreements including Sarepta ($825M upfront, up to $10B total potential), Novartis ($200M upfront, up to $2.2B total potential), and Madrigal ($25M upfront, up to $1B total potential). Revenue recognized upon milestone achievements and upfront payments.
  3. Milestone Payments: Development and regulatory milestone payments from partners including $200M from Sarepta for DM1 program progress, $200M from Novartis for Parkinson's partnership close, and $10M from Sanofi for China approval of REDEMPLO.
  4. Strategic Financing: Non-dilutive $500M credit facility with Sixth Street ($400M funded at close, $100M additional available) with maturity August 7, 2031. Used to fund pipeline development and commercial readiness.

Pricing tiers

ModelBillingPrice
Unit PricingAnnualREDEMPLO annual treatment at $60,000/year
Unit PricingAnnualREDEMPLO approved in US, Canada, China, Australia, and EU

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Arrowhead Pharmaceuticals product offering

Product offering

Core offering

Arrowhead Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics using its proprietary Targeted RNAi Molecule (TRiM) platform, which silences disease-causing genes across multiple tissue types including liver, lung, muscle, and CNS. The company currently markets REDEMPLO (plozasiran), an FDA-approved siRNA medicine for familial chylomicronemia syndrome, and is advancing a pipeline of over 14 clinical-stage RNAi candidates addressing cardiometabolic, pulmonary, CNS, and rare genetic diseases.

Product overview

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company that develops RNAi (RNA interference) therapeutics using its proprietary TRiM (Targeted RNAi Molecule) platform. The company has transitioned from a development-stage to a commercial-stage company following FDA approval of its first drug, REDEMPLO (plozasiran), in November 2025. The portfolio includes approved and pipeline products: REDEMPLO (plozasiran) for familial chylomicronemia syndrome is the company's first approved commercial product; Plozasiran (ARO-APOC3) is in Phase 3 for severe hypertriglyceridemia; Zodasiran (ARO-ANG3) is in Phase 3 for homozygous familial hypercholesterolemia; ARO-RAGE is in Phase 2 for inflammatory pulmonary diseases; obesity candidates ARO-INHBE and ARO-ALK7 are in Phase 1/2a; ARO-MAPT for Alzheimer's disease is in Phase 1/2a; and ARO-DIMER-PA for mixed hyperlipidemia is in Phase 1/2a. The TRiM platform enables targeted gene silencing across multiple tissue types.

Differentiator

Problem solved

Functional benefit

Brands

  • REDEMPLO: Brand name for plozasiran, the company's first FDA-approved siRNA medicine for familial chylomicronemia syndrome (FCS).
  • TRiM

Products and services

  • REDEMPLO (plozasiran) FDA-approved siRNA medicine that reduces Apolipoprotein-CIII (ApoC3) production through RNA interference to lower triglycerides in adults with familial chylomicronemia syndrome (FCS). Approved in the US, Canada, China, Australia, and the EU.
  • Plozasiran (ARO-APOC3) RNAi therapeutic in Phase 3 development for severe hypertriglyceridemia (SHTG), targeting ApoC3 to reduce triglyceride production. Pipeline expansion of the plozasiran program beyond the FCS indication.
  • Zodasiran (ARO-ANG3) RNAi therapeutic in Phase 3 development (YOSEMITE study) that reduces production of angiopoietin-like protein 3 (ANGPTL3), a liver-synthesized inhibitor of lipoprotein lipase, targeting cardiovascular disease and homozygous familial hypercholesterolemia.
  • ARO-RAGE RNAi therapeutic in Phase 2 development targeting the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various muco-obstructive and inflammatory pulmonary diseases.
  • ARO-INHBE RNAi therapeutic in Phase 1/2a development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), targeting the INHBE gene for differentiated weight loss and liver fat reduction.
  • ARO-ALK7 RNAi therapeutic in Phase 1/2a development for obesity, the first RNAi therapeutic to show knockdown of an adipocyte-expressed gene in humans. Targets the ALK7 gene for visceral fat reduction.
  • ARO-MAPT Investigational RNAi therapeutic in Phase 1/2a development designed to treat tauopathies including Alzheimer's disease. Uses the proprietary TRiM platform with subcutaneous delivery that crosses the blood-brain barrier to target tau protein (MAPT).
  • ARO-DIMER-PA First dual functional RNAi therapeutic in Phase 1/2a development for mixed hyperlipidemia, targeting both ANGPTL3 and ApoC3 simultaneously.

Quantifiable outcome

  • REDEMPLO achieved 80% median triglyceride reduction from baseline in FCS patients (Phase 3 PALISADE trial)
  • +5 more outcomes

Companies that use Arrowhead Pharmaceuticals

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Arrowhead Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Arrowhead Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • Madrigal PharmaceuticalscoreStrategic or Co-development Partner · 5 May 2026Licensed ARO-PNPLA3, an RNAi candidate targeting PNPLA3 I148M genetic mutation for MASH, to Madrigal Pharmaceuticals. Arrowhead received $25 million upfront with potential milestone payments totaling up to $975 million. The asset had been returned to Arrowhead after J&J rejected it. Madrigal intends to add ARO-PNPLA3 to its growing pipeline alongside FDA-approved Rezdiffra.
  • TakedacoreStrategic or Co-development Partner · 10 October 2025Co-development and co-commercialization agreement for ARO-AAT (fazirsiran) for Alpha-1 Antitrypsin Deficiency-associated liver disease. Arrowhead earned $40 million milestone when first patient was treated in Phase 3 SEQUOIA study. Takeda acquired additional programs from Arrowhead.
  • NovartiscoreStrategic or Co-development Partner · 2 September 2025Global license and collaboration agreement for ARO-SNCA targeting alpha-synuclein for Parkinson's disease and other synucleinopathies. Arrowhead received $200 million upfront payment with potential milestone payments up to $2 billion plus royalties. Arrowhead conducted preclinical research through CTA filing, after which Novartis assumes sole control over development, manufacturing, medical affairs, and commercialization. Deal closed in October 2025.
  • Sanofi (via Visirna subsidiary)secondaryChannel Partner/ Reseller/ Distributor · 1 August 2025Arrowhead subsidiary Visirna sold rights to plozasiran (hypertriglyceridemia candidate) in Greater China to Sanofi. Sanofi also received $10 million milestone payment from Arrowhead following China's approval of REDEMPLO for FCS in January 2026.
  • Sarepta TherapeuticscoreStrategic or Co-development Partner · 26 November 2024Global licensing and collaboration agreement for multiple clinical and preclinical RNAi programs targeting rare genetic diseases. Arrowhead received $825 million upfront payment with potential future payments up to $10 billion including milestones and royalties. Programs include SRP-1001 (FSHD), SRP-1003 (DM1), SRP-1005 (Huntington's), and additional candidates. Sarepta paid $500 million for rights to seven programs. Arrowhead earned $200 million milestone for DM1 program progress and $100 million milestone in July 2025.
  • Roche/JanssensecondaryStrategic or Co-development Partner · 31 October 2024Janssen partnership ended in 2023 after Janssen cut its infectious disease and vaccine units. Johnson & Johnson liquidated its Arrowhead stake in 2026, exiting the relationship. Roche collaboration on hepatitis B programs continued through various arrangements.

Scale indicators7 records

Recent moves6 records

Expansion highlights8 records

Arrowhead Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: The leading siRNA therapeutics company and the closest direct peer. Alnylam has multiple approved siRNA drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio) and a similar platform-based approach to gene silencing. Both companies compete for the same large-pharma partnership economics and target overlapping indications.
  • Ionis Pharmaceuticals: Direct competitor in antisense oligonucleotide therapeutics with an approved FCS drug (Tryngolza/olezarsen) that competes head-to-head with Arrowhead's REDEMPLO. Ionis and Arrowhead target the same cardiometabolic and rare disease indications through RNA-based approaches, making them direct strategic peers.

Emerging players

  • Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotide therapeutics. Comparable to Arrowhead in being an RNA-focused biotech with similar pipeline-stage assets and partnership-driven business model, though smaller and earlier-stage.
  • Silence Therapeutics: Clinical-stage siRNA therapeutics company developing mRNAi GOLD platform. Comparable to Arrowhead as an siRNA-focused player with cardiovascular pipeline assets (e.g., SLN360 for Lp(a)). Smaller and earlier-stage but pursues similar siRNA therapeutic strategy.
  • Madrigal Pharmaceuticals: MASH-focused biopharma with FDA-approved Rezdiffra, and a current Arrowhead partner (licensed ARO-PNPLA3 in May 2026). Comparable commercial-stage liver/metabolic biotech that validates Arrowhead's MASH pipeline asset and illustrates the typical scale and profile of Arrowhead's partner counterparties.
  • Viridian Therapeutics: Clinical-stage rare disease biopharma focused on FcRn inhibitors (autoimmune) and anti-IGF-1R antibodies (thyroid eye disease). Comparable commercial-stage rare-disease biotech at similar development phase and market cap tier to Arrowhead's pre-launch REDEMPLO era.

Broad incumbents

  • Sarepta Therapeutics: Arrowhead's largest strategic partner ($10B potential deal), and a leading rare-disease genetic medicine company. While not a direct therapeutic competitor (Sarepta focuses on gene therapy/DMD), it is a benchmark partner of comparable scale and validates the platform's commercial appeal.
  • Moderna: Broader RNA therapeutics incumbent (mRNA-based) with established platform, commercial product, and large-scale manufacturing. Comparable as a public RNA-therapeutics leader but operates with different technology (mRNA vs siRNA) and at greater scale across infectious disease and oncology.
  • BioNTech: mRNA therapeutics leader with diversified pipeline in oncology and infectious disease. Comparable as a public, platform-based RNA therapeutics company with similar scientific ambitions and capital markets profile, though at much larger scale.

Others

  • Royalty Pharma: Financial partner that purchased Arrowhead's olpasiran royalty interest for $250M in 2024. Listed as an ecosystem/adjacent participant that funds biopharma innovation through royalty transactions, illustrating the broader capital-market infrastructure that supports RNAi asset development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Arrowhead Pharmaceuticals social profiles

Digital presence

Arrowhead Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arrowhead Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Arrowhead Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Arrowhead Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arrowhead Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arrowhead Pharmaceuticals

What does Arrowhead Pharmaceuticals do?

Arrowhead Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics using its proprietary Targeted RNAi Molecule (TRiM) platform, which silences disease-causing genes across multiple tissue types including liver, lung, muscle, and CNS. The company currently markets REDEMPLO (plozasiran), an FDA-approved siRNA medicine for familial chylomicronemia syndrome, and is advancing a pipeline of over 14 clinical-stage RNAi candidates addressing cardiometabolic, pulmonary, CNS, and rare genetic diseases.

Is Arrowhead Pharmaceuticals a public or private company?

Arrowhead Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Arrowhead Pharmaceuticals founded?

Arrowhead Pharmaceuticals was founded in 2012. It employs 501 to 1,000 people.

Where is Arrowhead Pharmaceuticals based?

Arrowhead Pharmaceuticals is headquartered in Pasadena, United States, in the North America region.

How does Arrowhead Pharmaceuticals make money?

Four revenue lines are on record. Product Sales are the primary driver. The others are licensing and Milestone Payments, milestone Payments and strategic Financing.

Who are Arrowhead Pharmaceuticals's main competitors?

Direct peers on record are Alnylam Pharmaceuticals and Ionis Pharmaceuticals. Emerging players are Wave Life Sciences, Silence Therapeutics, Madrigal Pharmaceuticals and Viridian Therapeutics. Broad incumbents are Sarepta Therapeutics, Moderna and BioNTech. Royalty Pharma is listed as an others.

Does Arrowhead Pharmaceuticals have an API?

No public API is recorded for Arrowhead Pharmaceuticals.

What industry is Arrowhead Pharmaceuticals in?

Arrowhead Pharmaceuticals's product category is RNAi Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaArrowhead Pharmaceuticals, Inc. (ARWR) Presents at Jefferies Global Healthcare Conference 2026 TranscriptArrowhead Pharmaceuticals CEO Christopher Anzalone presented at Jefferies' Global Healthcare Conference, detailing its RNAi platform with 23 clinical drug candidates. He announced Redemplo, an siRNA for familial chylomicronemia syndrome, filed an sNDA to expand to severe hypertriglyceridemia, with approval expected in March or April.YahooCould RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?Arrowhead Pharmaceuticals reported full year 2026 revenue of $450.82 million, down from $829.45 million, and a net loss of $724.21 million. The company refinanced a $400 million term loan at SOFR plus 5.5% interest, reducing costs. Analysts expect revenue of $1 billion and earnings of $194.9 million by 2029.The future of tradingArrowhead Pharmaceuticals grants up to 196,885 restricted stock units to 203 new employeesArrowhead Pharmaceuticals awarded 203 new employees grants totaling up to 196,885 restricted stock units. The grants, approved on October 22, 2026, vest annually over four years under stockholder-approved equity incentive plans.YahooArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Arrowhead Pharmaceuticals approved inducement grants to 203 new employees on October 22, 2026, under NASDAQ Listing Rule 5635(c)(4). The grants entitle employees to up to 196,885 restricted stock units, vesting annually over four years, and are outside the company's stockholder-approved equity incentive plans.Stock TitanArrowhead grants 203 hires up to 196,885 RSUs totalArrowhead Pharmaceuticals approved inducement grants to 203 new employees on October 22, 2026, under NASDAQ Rule 5635(c)(4). The grants entitle employees to receive up to 196,885 restricted stock units, vesting annually over four years, and are outside the company's stockholder-approved equity incentive plans.The Pharma LetterArrowhead shares end week down 18% after Ionis’s Tryngolza stumble casts doubt on sHTG launchArrowhead Pharmaceuticals shares fell 17.8% to $47.78 after Ionis Pharmaceuticals halved its 2026 sales guidance for Tryngolza, the drug Arrowhead plans to launch as Redemplo. The stock dropped about 15% on Monday, then further 4.5% on Thursday, before recovering 1.3% on Friday.Simply Wall StAnalysts Have Lowered Expectations For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) After Its Latest ResultsArrowhead Pharmaceuticals reported Q4 revenue of $451m, missing expectations, and a statutory loss of $5.11 per share, 42% larger than predicted. Analysts now forecast 2027 revenue of $306.6m, down 32% from last year, and losses of $5.53 per share, while the average price target remains at $106.TradingViewRBC Capital maintains Arrowhead Pharma at Outperform, keeps price target at $100RBC Capital maintained Arrowhead Pharma at Outperform with a $100 price target, implying 112.1% upside from the Nov 12 close of $47.15. Recent analyst price targets range from $96 to $120.TradingViewStifel maintains Arrowhead Pharma at Buy, lowers price target to $96 from $104Stifel maintained Arrowhead Pharma at Buy and lowered its price target to $96 from $104, a 7.7% decrease. The target implies an upside of 103.6% from the Nov 12 close of $47.15. Recent analyst price targets range from $109 to $120.